Abstract
Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was generated from an attenuated, recombinant herpes simplex virus. T-VEC has demonstrated therapeutic activity in melanoma patients and is being tested in a number of other cancers alone and in combination with standard cancer therapeutics and other immunotherapy agents. This review will discuss the current landscape of melanoma, the construction and application of T-VEC for melanoma along with other indications for T-VEC, as well as highlight some of the novel challenges with oncolytic virus immunotherapy as it enters into clinical practice.
Original language | English (US) |
---|---|
Pages (from-to) | 549-558 |
Number of pages | 10 |
Journal | Drugs of Today |
Volume | 51 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2015 |
Externally published | Yes |
Keywords
- Cancer immunotherapy
- Melanoma
- OncoVEX
- Oncolytic virus
- Talimogene laherparepvec
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)